2016 Annual Meeting
SC40-Hematolymphoid Lesions at the Borderline Between Benign and Malignant - Finding Your Way Out of Uncertainty
Room CC Ballroom 6 C, March 17 2016, 8:00am to 11:30am
SC40-Hematolymphoid Lesions At The Borderline Between Benign And Malignant - Finding Your Way Out Of Uncertainty
Session Credits: 3 CME and 3 SAMs
Faculty: Eric D. Hsi, MD, Cleveland Clinic, Cleveland, OH; Carlos E. Bueso-Ramos, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX and Megan O. Nakashima, MD, Cleveland Clinic, Cleveland, OH
There are several hematolymphoid lesions which are at the interface between processes which are clearly malignant and others which are clinically benign, including in situ lymphomas, EBV-associated lymphoproliferative disorders, and idiopathic cytopenias of undetermined significance. As more data is accumulated our understanding of these entities is constantly evolving. Despite increases in knowledge, these borderline lesions remain difficult to diagnose. This course will be based on case examples which will be available for review as digital slides and static images prior to the meeting. It is designed for pathologists in training, and practicing hematopathologists and surgical pathologists. After the course, registrants will be given access to PowerPoint slides used during the presentation. Topics to be discussed include in situ lymphomas, cutaneous pseudolymphomas, clonal T-cell populations detected during immune-altered states, monoclonal gammopathy of undetermined significance, non-post transplant EBV-associated lymphoproliferative disorders, chronic eosinophila, and idiopathic cytopenia of undermined significance, as well as other related lesions. Emphasis will be placed on morphologic features and differential diagnosis of these entities, as well as guidance regarding appropriate ancillary testing. A brief review of current understanding of pathogenesis and prognosis will also be discussed for each lesion.
Upon completion of this educational activity the participants should:
- Recognize and diagnose these challenging lesions and differentiate them from potential diagnostic pitfalls
- Know what ancillary testing is appropriate in the diagnostic workup of these lesions, and through an updated understanding of the biology of these processes
- Construct meaningful diagnostic report for their clinical colleagues.